Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
How Did Tempus AI Power Its Move to Positive EBITDA in Q3?
09:56am, Monday, 17'th Nov 2025
TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.
AE Wealth Management LLC Buys Shares of 4,517 Tempus AI, Inc. $TEM
03:29am, Monday, 17'th Nov 2025
AE Wealth Management LLC acquired a new stake in shares of Tempus AI, Inc. (NASDAQ: TEM) during the second quarter, according to the company in its most recent filing with the Securities and Exchange
Tempus AI: Opportunity To Build Position
10:00am, Saturday, 15'th Nov 2025
Tempus AI has pulled back with the broader AI sector, presenting a renewed buying opportunity after strong Q3 results. TEM's Q3 sales surged 85% to $334 million, largely driven by the Ambry acquisitio
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
12:03pm, Friday, 14'th Nov 2025
Cathie Wood added to her stakes in Circle Internet Group, Bitmine Immersion, and Tempus AI on Thursday. The three stocks fell as much as 10% on Thursday, giving Ark Invest a chance to add on a dip.
TEM Continues to Strengthen Its Genomics Leadership With New Products
09:01am, Friday, 14'th Nov 2025
Tempus AI advances its genomics push with new assays, CDx progress and plans for whole-genome sequencing to drive future growth.
Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
08:30am, Friday, 14'th Nov 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and bei
Tempus AI, Inc. (TEM) Presents at Stifel 2025 Healthcare Conference Transcript
12:11pm, Thursday, 13'th Nov 2025
Tempus AI, Inc. ( TEM ) Stifel 2025 Healthcare Conference November 13, 2025 10:00 AM EST Company Participants James Rogers - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel,
Tempus AI: Great Buying Opportunity On Recent Weakness
09:59am, Thursday, 13'th Nov 2025
Tempus AI stands out as a leader in healthcare AI, showing strong execution and robust Q3 results despite recent stock volatility. TEM reported 85% revenue growth, expanding gross margins, and solid p
Tempus AI: A Good Bet For The Future Of Health Care
05:34pm, Wednesday, 12'th Nov 2025
Tempus AI remains a buy as its data set, testing volumes, and financial results continue to show robust growth. TEM's Genomics segment drives strong revenue growth, with oncology and hereditary testin
Cathie Wood doubles down on Alibaba: ARK Invest snaps up $25M in Chinese tech stocks
07:02am, Wednesday, 12'th Nov 2025
ARK Invest funds boosted holdings in Alibaba (BABA) and Baidu (BIDU) while trimming stakes in Reddit (RDDT), Exact Sciences (EXAS) and Iridium Communications (I
Should You Buy, Hold or Sell TEM Stock Post Q3 Earnings Release?
08:31am, Tuesday, 11'th Nov 2025
Tempus AI posts first positive adjusted EBITDA and 84.7% revenue surge, signaling new growth momentum amid premium valuation.
Tempus AI: First Positive EBITDA, Huge TAM - Yet The Stock Isn't A Buy
09:55pm, Monday, 10'th Nov 2025
Tempus AI is building a strong moat in healthcare AI with vast clinical/genomic datasets and robust infrastructure, driving high-growth potential. TEM achieved its first positive adjusted EBITDA in Q3
Tempus AI: Volatility Equates to Opportunity in AI Leader
01:23pm, Thursday, 06'th Nov 2025
Tempus AI's NASDAQ: TEM stock price pulled back in early November following its Q3 release, aligning with broader market action and opening a buying opportunity for investors. The primary concern is t
Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says
01:00pm, Wednesday, 05'th Nov 2025
BTIG analyst Mark Massaro reiterated a Buy rating for Tempus AI, Inc. (NASDAQ:TEM) with a price target of $96 following the third-quarter FY25 earnings beat.
TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours
12:06pm, Wednesday, 05'th Nov 2025
Tempus AI reports a narrower-than-expected Q3 loss and stronger revenues, raises full-year outlook, but shares decline following the results.
